<DOC>
	<DOCNO>NCT01842360</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety biological vaccine ( MV130 subject Chronic Obstructive Pulmonary Disease ( COPD ) compare placebo group .</brief_summary>
	<brief_title>Evaluation Efficacy Safety MV130 Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>Double blind parallel placebo control study . The subject receive medication 12 month follow another six month</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Written inform consent . Both gender Age 35 85 . Must able follow treatment regimen Diagnosis moderate COPD accord GOLD criterion Consumption 10 pack cigarettes/year Fertile woman must use approved contraceptive method Pregnant woman , breastfeed Subject participate study clinical trial investigational product last 3 month inclusion Subject severe COPD Subject history hypersensitivity component vaccine Subject outside age range Subject diagnose asthma Subject exacerbation 4 week start trial . Subject need corticosteroid last 4 week start trial Subject diagnose Primary Secondary Immunodeficiency Subjects chronic lymphoproliferative disease Subjects chronic infectious disease Subject chronic heart disease , arrhythmia , episodes arrhythmia secondary administration bronchodilator . Subject diagnose COPD chronic colonization Pseudomonas aeruginosa</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Chronic obstructive pulmonary disease ( COPD )</keyword>
</DOC>